Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
You may also be interested in...
Avacta To Evaluate Affimers As Checkpoint Inhibitors, Anticoagulants
After raising $34 million from Britain’s stock market, the U.K. biotech now plans to develop its Affimer proteins as therapeutics as well as research reagents, to enable two complementary strands of business.
Deals Of The Week Looks At Pricing Conundrums
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.